AustinPx Expands Access to KinetiSol Technology with New Leasing Model

• AustinPx has launched KinetiLease, a program allowing pharmaceutical companies to lease its KinetiSol research-scale equipment for in-house R&D.

• The first lease has been signed with a top 10 global biotech company, which has already begun applying the technology across multiple drug programs.

AustinPx has introduced KinetiLease, a leasing program designed to provide pharmaceutical companies direct access to its KinetiSol research-scale equipment. The initiative enables companies to integrate this amorphous dispersion manufacturing tool into their own R&D labs, supporting drug development efforts for poorly soluble small molecules.

KinetiSol Technology facilitates the creation of amorphous solid dispersions (ASD) without solvents, improving bioavailability, compressibility, and formulation efficiency. The technology has been applied across more than sixty molecules in the last three years through AustinPx’s contract manufacturing services. Now, companies can access it independently through the leasing model.

“By offering leasing options for KinetiSol equipment, AustinPx is empowering pharmaceutical companies to harness this game-changing technology, rapidly exploring the Technology across their drug pipeline,” said Elizabeth Hickman, CEO of AustinPx.

The program includes comprehensive training, white-glove delivery and installation, and annual preventive maintenance. AustinPx has already signed its first lease agreement with a major global biotech company, which began screening small molecule candidates within two weeks of installation and training.

With its compact design and efficiency, KinetiSol offers a streamlined alternative for developing ASD formulations. The KinetiLease program provides pharmaceutical and biotech firms with a flexible, cost-effective solution to enhance their in-house drug development capabilities.